CA3204013A1 - In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells - Google Patents

In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells

Info

Publication number
CA3204013A1
CA3204013A1 CA3204013A CA3204013A CA3204013A1 CA 3204013 A1 CA3204013 A1 CA 3204013A1 CA 3204013 A CA3204013 A CA 3204013A CA 3204013 A CA3204013 A CA 3204013A CA 3204013 A1 CA3204013 A1 CA 3204013A1
Authority
CA
Canada
Prior art keywords
cells
cell
human
endocrine
endoderm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204013A
Other languages
English (en)
French (fr)
Inventor
Alan Agulnick
Kevin D'amour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viacyte Inc filed Critical Viacyte Inc
Publication of CA3204013A1 publication Critical patent/CA3204013A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/195—Heregulin, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3204013A 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells Pending CA3204013A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781005P 2013-03-14 2013-03-14
US61/781,005 2013-03-14
US14/106,330 US8859286B2 (en) 2013-03-14 2013-12-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US14/106,330 2013-12-13
CA2897984A CA2897984C (en) 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2897984A Division CA2897984C (en) 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells

Publications (1)

Publication Number Publication Date
CA3204013A1 true CA3204013A1 (en) 2014-10-02

Family

ID=51527928

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3204013A Pending CA3204013A1 (en) 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
CA2897984A Active CA2897984C (en) 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2897984A Active CA2897984C (en) 2013-03-14 2014-03-13 In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells

Country Status (12)

Country Link
US (6) US8859286B2 (https=)
EP (2) EP3521418A1 (https=)
JP (7) JP6219494B2 (https=)
KR (7) KR102288191B1 (https=)
AU (6) AU2014243791B2 (https=)
CA (2) CA3204013A1 (https=)
DK (1) DK2970899T3 (https=)
ES (1) ES2739082T3 (https=)
IL (4) IL294691B2 (https=)
RU (3) RU2734657C2 (https=)
SG (2) SG11201505866RA (https=)
WO (1) WO2014160413A1 (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
KR101731474B1 (ko) 2008-02-21 2017-05-11 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
PL2310492T3 (pl) 2008-06-30 2015-12-31 Janssen Biotech Inc Różnocowanie pluripotencjalnych komórek macierzystych
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
ES2642070T3 (es) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivo de células madre pluripotentes en microportadores
ES2584053T3 (es) 2008-11-20 2016-09-23 Janssen Biotech, Inc. Métodos y composiciones para la unión de células y cultivo en sustratos planos
KR102058901B1 (ko) 2009-07-20 2019-12-24 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
EP2542667A4 (en) 2010-03-01 2013-07-31 Janssen Biotech Inc PROCESS FOR CLEANING CELLS OBTAINED FROM PLURIPOTENTIAL STEM CELLS
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
US10213746B2 (en) 2016-04-14 2019-02-26 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
USD933584S1 (en) 2012-11-08 2021-10-19 Sunpower Corporation Solar panel
USD1009775S1 (en) 2014-10-15 2024-01-02 Maxeon Solar Pte. Ltd. Solar panel
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
WO2014164621A1 (en) 2013-03-12 2014-10-09 Lockheed Martin Corporation Method for forming filter with uniform aperture size
SG11201510177WA (en) 2013-06-11 2016-01-28 Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
SG11201606287VA (en) 2014-01-31 2016-08-30 Lockheed Corp Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
CN106536718B (zh) 2014-05-21 2021-04-27 国立大学法人京都大学 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
MX2017002738A (es) 2014-09-02 2017-08-02 Lockheed Corp Membranas de hemodialisis y hemofiltracion basadas en un material de membrana bidimensional y metodos que emplean las mismas.
CN107075471A (zh) * 2014-10-08 2017-08-18 新加坡科技研究局 将干细胞分化为肝细胞谱系的方法
USD913210S1 (en) 2014-10-15 2021-03-16 Sunpower Corporation Solar panel
USD896747S1 (en) 2014-10-15 2020-09-22 Sunpower Corporation Solar panel
USD999723S1 (en) 2014-10-15 2023-09-26 Sunpower Corporation Solar panel
USD933585S1 (en) 2014-10-15 2021-10-19 Sunpower Corporation Solar panel
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
AU2015363008B2 (en) 2014-12-19 2021-12-09 Janssen Biotech, Inc. Suspension culturing of pluripotent stem cells
WO2016104541A1 (ja) * 2014-12-24 2016-06-30 国立大学法人京都大学 内胚葉系細胞の製造方法、肝臓細胞の製造方法、膵臓細胞の製造方法、内胚葉系細胞の誘導促進剤、肝臓細胞の誘導促進キット、膵臓細胞の誘導促進キット、およびマイクロ流体デバイス
CA2979293C (en) 2015-03-11 2022-01-04 Timothy J. Kieffer Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
KR102598772B1 (ko) 2015-04-03 2023-11-03 프로파제닉스 인크. 상피 세포의 생체외 증식
JP2016202172A (ja) 2015-04-16 2016-12-08 国立大学法人京都大学 疑似膵島の製造方法
EP3081633A1 (en) 2015-04-16 2016-10-19 ARKRAY, Inc. Device and system for cell culture
CA2983764A1 (en) 2015-04-24 2016-10-27 University Of Copenhagen Isolation of bona fide pancreatic progenitor cells
WO2017023376A1 (en) 2015-08-05 2017-02-09 Lockheed Martin Corporation Perforatable sheets of graphene-based material
JP2018530499A (ja) 2015-08-06 2018-10-18 ロッキード・マーチン・コーポレーション グラフェンのナノ粒子変性及び穿孔
EP3892718A1 (en) * 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells
JP6937513B2 (ja) * 2015-09-11 2021-09-22 国立研究開発法人理化学研究所 転写因子結合部位特異的なｄｎａ脱メチル化方法
US10370637B2 (en) 2015-12-15 2019-08-06 The Regents Of The University Of California Technology for sustaining pluripotency and improved growth of stem cells in culture
KR20180133430A (ko) 2016-04-14 2018-12-14 록히드 마틴 코포레이션 결함 형성 또는 힐링의 인 시츄 모니터링 및 제어를 위한 방법
DK3443073T3 (da) 2016-04-14 2024-09-02 Janssen Biotech Inc Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller
EP3442739A4 (en) 2016-04-14 2020-03-04 Lockheed Martin Corporation PROCESS FOR PROCESSING GRAPHENE SHEETS FOR LARGE SCALE TRANSFER USING A FREE FLOATING PROCESS
KR20190018410A (ko) 2016-04-14 2019-02-22 록히드 마틴 코포레이션 흐름 통로들을 갖는 2차원 막 구조들
KR102729404B1 (ko) 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
DK3537986T3 (da) 2016-11-10 2025-07-21 Viacyte Inc Pdx1 pankreatiske endodermceller i celleleveringsanordning
USD824042S1 (en) 2016-11-10 2018-07-24 Viacyte, Inc. Perforated cell encapsulation device
WO2018094107A1 (en) * 2016-11-17 2018-05-24 Baylor College Of Medicine Recreation of pancreatic niche allows for novel methods for human, mature beta derivation from pluripotent stem cells
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
CN110392735A (zh) * 2017-01-17 2019-10-29 新加坡科技研究局 胰腺祖细胞的维持和扩增
CN110997904B (zh) * 2017-03-21 2024-11-26 法国血液机构 改进造血移植物的方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
EP3654996A4 (en) * 2017-07-21 2021-03-24 Semma Therapeutics, Inc. REAGGREGATION OF PANCREAS BETA CELLS FROM STEM CELLS
AU2018330499B2 (en) * 2017-09-11 2025-01-30 Novo Nordisk A/S Enrichment of NKX6.1 and C-peptide co-expressing cells derived in vitro from stem cells
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
CA2983845C (en) 2017-10-26 2024-01-30 University Of Copenhagen Generation of glucose-responsive beta cells
KR20250048146A (ko) * 2017-11-15 2025-04-07 셈마 테라퓨틱스, 인크. 섬세포 제조 조성물 및 사용 방법
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11530211B2 (en) 2018-01-18 2022-12-20 Daiichi Sankyo Company, Limited Dihydroindolizinone derivative
WO2019151098A1 (ja) * 2018-01-30 2019-08-08 株式会社片岡製作所 インスリン産生細胞の製造方法
CN112074281A (zh) * 2018-03-02 2020-12-11 沃泰克斯药物股份有限公司 增强干细胞向β细胞分化的方法
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
EP4386081A3 (en) * 2019-05-21 2024-10-16 President and Fellows of Harvard College Endocrine differentiation-inducing molecule
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2020243666A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CN114401752B (zh) 2019-05-31 2023-04-04 W.L.戈尔及同仁股份有限公司 具有受控氧扩散距离的细胞封装装置
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
WO2020243665A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
WO2020243633A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
AU2020329194A1 (en) * 2019-08-13 2022-02-24 Children's Hospital Medical Center Improved methods for making organoid compositions
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
AU2020364053A1 (en) * 2019-10-10 2022-05-26 University Of Houston System Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells, and uses related thereto
JP7721105B2 (ja) * 2020-01-17 2025-08-12 国立大学法人京都大学 膵内胚葉細胞の増殖を促進する方法及びキット
US20230392124A1 (en) * 2020-04-16 2023-12-07 Washington University Methods and compositions for improving sc-beta cells or enhancing their utility
CN113637630B (zh) * 2020-05-11 2024-03-29 中国科学院分子细胞科学卓越创新中心 一种胰岛样细胞团及其制法和应用
IL300105A (en) 2020-07-31 2023-03-01 Vertex Pharma Pancreatic endocrine cell differentiation
CN116018150A (zh) * 2020-08-28 2023-04-25 诺和诺德股份有限公司 用于筛选干细胞衍生的β样细胞的体外群体的方法及其新型标志物
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
CN114350598A (zh) * 2021-12-03 2022-04-15 深圳华源再生医学有限公司 一种多能干细胞体外形成3d球的培养方法
EP4508645A1 (en) 2022-04-15 2025-02-19 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
US20250283046A1 (en) 2022-04-21 2025-09-11 Evotec International Gmbh New Cell Populations and Means and Methods for their Differentiation and Preservation
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US800807A (en) 1905-04-03 1905-10-03 Hans P Larsen Composition of matter for soldering.
US2161804A (en) 1935-11-09 1939-06-13 Baldwin Southwark Corp Hydraulic press
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
DK0641781T3 (da) 1991-09-06 2000-09-18 Yoshitomi Pharmaceutical 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US20030059913A1 (en) 1995-11-20 2003-03-27 Walter Weyler Novel Microorganisms with ability to degrade indole and novel enzymes therefrom
AU2192997A (en) 1996-02-28 1997-09-16 Vanderbilt University Compositions and methods of making embryonic stem cells
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
CA2397543A1 (en) 2000-01-24 2001-07-26 Timothy Harrison Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
AU2002210747B2 (en) 2000-11-02 2006-06-01 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
JP2002184539A (ja) 2000-12-14 2002-06-28 Auto Network Gijutsu Kenkyusho:Kk コネクタ
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
JP2003097552A (ja) 2001-09-21 2003-04-03 Nsk Ltd 摩擦付加装置および直動案内装置
US20030062225A1 (en) 2001-10-03 2003-04-03 Stucky Paul A. Elevator load bearing assembly having a detectable element that is indicative of local strain
US20030077256A1 (en) * 2001-10-19 2003-04-24 Paul Czernichow Pancreas regeneration using embryonic pancreatic cells
CA2470539C (en) 2001-12-07 2011-10-04 Geron Corporation Islet cells from human embryonic stem cells
GB2398559B (en) 2001-12-13 2005-12-21 Gen Binding Corp Transportation system for sheet delivery between sheet or sheet stack processing equipment
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US20040039796A1 (en) 2002-08-08 2004-02-26 Virtual Radio, Inc. Personalized cyber disk jockey and Internet radio advertising
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
RU2340330C2 (ru) 2002-10-11 2008-12-10 НОВОСЕЛЛ, Инк Имплантация инкапсулированных биологических материалов для лечения заболеваний
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
CN103898047B (zh) 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
JP4901471B2 (ja) 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
US8597947B2 (en) * 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
US7739764B2 (en) 2005-04-27 2010-06-22 Whirlpool Corporation Method and apparatus for monitoring load size and load imbalance in washing machine
AU2006305879B2 (en) 2005-10-27 2012-05-10 Viacyte, Inc. PDX1-expressing dorsal and ventral foregut endoderm
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
KR20080109775A (ko) 2006-02-23 2008-12-17 노보셀, 인크 분화가능한 세포를 배양하는데 유용한 조성물 및 방법
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
AU2007254766A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
DK177279B1 (da) 2006-07-27 2012-09-24 Vegano Aps Ukrudtsmiddel samt fremgangsmåde til fremstilling
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
WO2009012428A2 (en) * 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
RU2391401C2 (ru) * 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
RU2359030C1 (ru) * 2008-03-19 2009-06-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты)
EP2283117B1 (en) * 2008-04-21 2013-10-23 Viacyte, Inc. Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
WO2009154606A1 (en) 2008-06-03 2009-12-23 Cythera, Inc. Growth factors for production of definitive endoderm
US20090298178A1 (en) 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
EP2356213B1 (en) 2008-11-04 2019-05-29 Viacyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
AU2009313870B2 (en) 2008-11-14 2013-07-11 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
JP5488000B2 (ja) 2009-02-02 2014-05-14 リコーイメージング株式会社 高変倍ズームレンズ系
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
WO2010135639A2 (en) * 2009-05-21 2010-11-25 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
SG177483A1 (en) * 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
CA2784425A1 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
WO2011090755A2 (en) 2009-12-29 2011-07-28 Fori Automation, Inc. Drive mechanism for automated guided vehicle
US8424928B2 (en) 2010-09-24 2013-04-23 Thase Enterprise Co., Ltd. Door handle having a handgrip changeable indoor and outdoor
US20120270890A1 (en) 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
CN104703862B (zh) 2012-10-01 2017-05-24 日产自动车株式会社 稳定性控制装置
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
DE102013212018A1 (de) 2013-06-25 2015-01-08 Evonik Industries Ag Metalloxid-Prekursoren, sie enthaltende Beschichtungszusammensetzungen, und ihre Verwendung
US10702008B2 (en) 2018-02-26 2020-07-07 Hbn Shoe, Llc Device and method of constructing shoes
SG11202112875UA (en) 2019-06-20 2021-12-30 Chemocentryx Inc Compounds for treatment of pd-l1 diseases
US12108408B2 (en) 2020-10-01 2024-10-01 Qualcomm Incorporated Providing cross-carrier scheduling control information for a primary cell via both a secondary cell and the primary cell
US11586805B2 (en) 2021-07-26 2023-02-21 Atlassian Pty Ltd. Machine-learning-based natural language processing techniques for low-latency document summarization
US12463142B1 (en) 2021-10-01 2025-11-04 Kepler Computing Inc. Integrating embedded memory with logic interconnects

Also Published As

Publication number Publication date
JP6654664B2 (ja) 2020-02-26
JP6355802B2 (ja) 2018-07-11
DK2970899T3 (da) 2019-08-12
JP7490035B2 (ja) 2024-05-24
SG11201505866RA (en) 2015-08-28
KR20200015855A (ko) 2020-02-12
SG10201610787XA (en) 2017-02-27
KR102077367B1 (ko) 2020-02-13
RU2734657C2 (ru) 2020-10-21
JP2020096605A (ja) 2020-06-25
US9650610B2 (en) 2017-05-16
RU2764465C1 (ru) 2022-01-17
AU2021202943A1 (en) 2021-06-03
AU2021266324C1 (en) 2023-06-08
US20230165908A1 (en) 2023-06-01
JP2018183142A (ja) 2018-11-22
AU2021202943C1 (en) 2022-02-24
AU2021266324A1 (en) 2021-12-09
KR102328311B1 (ko) 2021-11-19
JP2023029922A (ja) 2023-03-07
KR102231393B1 (ko) 2021-03-25
IL283094A (en) 2021-06-30
EP3521418A1 (en) 2019-08-07
JP2016513972A (ja) 2016-05-19
KR20150127063A (ko) 2015-11-16
US20240299462A1 (en) 2024-09-12
KR20210034100A (ko) 2021-03-29
WO2014160413A1 (en) 2014-10-02
KR20210100743A (ko) 2021-08-17
RU2670064C2 (ru) 2018-10-17
KR102288191B1 (ko) 2021-08-11
IL240028B (en) 2021-05-31
AU2014243791A1 (en) 2015-07-30
IL294691B1 (en) 2025-02-01
KR20240134215A (ko) 2024-09-06
JP2024112871A (ja) 2024-08-21
CA2897984C (en) 2023-08-22
RU2015137400A (ru) 2017-04-18
AU2019202849A1 (en) 2019-05-16
EP2970899B1 (en) 2019-05-08
KR102187510B1 (ko) 2020-12-08
KR102698731B1 (ko) 2024-08-27
US11446335B2 (en) 2022-09-20
JP2022017361A (ja) 2022-01-25
ES2739082T3 (es) 2020-01-28
AU2014243791B2 (en) 2019-01-31
IL294691A (en) 2022-09-01
AU2023201602A1 (en) 2023-04-13
US20140271566A1 (en) 2014-09-18
US8859286B2 (en) 2014-10-14
US20190307810A1 (en) 2019-10-10
JP6966583B2 (ja) 2021-11-17
RU2018134644A (ru) 2019-03-21
AU2019264658B2 (en) 2021-02-18
CA2897984A1 (en) 2014-10-02
JP7187647B2 (ja) 2022-12-12
US20150017135A1 (en) 2015-01-15
US20170202885A1 (en) 2017-07-20
AU2023201602B2 (en) 2025-03-20
AU2019202849B2 (en) 2019-08-22
IL317491A (en) 2025-02-01
JP2018007670A (ja) 2018-01-18
US10376545B2 (en) 2019-08-13
KR20200138434A (ko) 2020-12-09
IL240028A0 (en) 2015-09-24
AU2021202943B2 (en) 2021-08-19
RU2018134644A3 (https=) 2019-03-21
KR20210142763A (ko) 2021-11-25
AU2021266324B2 (en) 2022-12-22
EP2970899A1 (en) 2016-01-20
AU2019264658A1 (en) 2019-12-05
IL294691B2 (en) 2025-06-01
JP6219494B2 (ja) 2017-10-25

Similar Documents

Publication Publication Date Title
AU2023201602B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
CA2898431C (en) Cell compositions derived from dedifferentiated reprogrammed cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230619

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241016

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250207

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250530

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251103

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260212